benzhydrazone: selective inhibitor of herpes simplex virus glycoprotein synthesis; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 5477413 |
| MeSH ID | M0089496 |
| Synonym |
|---|
| benzhydrazone |
| 76788-93-7 |
| 1h-benz(f)indene-1,3(2h)dione-bis-amidinohydrazone |
| hydrazinecarboximidamide, 2,2'-(1h-benz(f)indene-1,3(2h)-diylidene)bis-, dihydrochloride |
Benzhydrazone (BH) is an inhibitor of glycoprotein biosynthesis. It specifically hinders the formation of herpes simplex virus (HSV) glycoproteins.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Benzhydrazone is a bis-amidinohydrazone derivative which specifically hinders the formation of herpes simplex virus (HSV) glycoproteins. " | ( Studies on benzhydrazone, a specific inhibitor of herpesvirus glycoprotein synthesis. Size distribution of glycopeptides and endo-beta-N-acetylglucosaminidase-H treatment. Campadelli-Fiume, G; Serafini-Cessi, F, 1981) | 2.1 |
| "Benzhydrazone (BH) is an inhibitor of glycoprotein biosynthesis. " | ( A herpes simplex virus type 1 mutant resistant to benzhydrazone, an inhibitor of glycoprotein synthesis in herpesvirus-infected cells. Preliminary mapping of benzhydrazone-resistance and of a novel syncytial mutation. Campadelli-Fiume, G; Foà-Tomasi, L; Gatti, R; Manservigi, R; Romanelli, MG; Rotola, A; Tognon, M, 1988) | 1.97 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 7 (77.78) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.87) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (11.11%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (88.89%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||